JATT III Acquisition, a blank check company formed by biotech entrepreneurs targeting life sciences businesses, filed on Monday with the SEC to raise up to $60 million in an initial public offering.
The company plans to raise $60 million by offering 6 million shares at $10. Unlike most SPACs, the company is not offering units with warrants or rights attached.
JATT II Acquisition is led by CEO and Chairman Someit Sidhu, who has founded and led several healthcare companies, most recently Khanda Therapeutics, where he serves as CEO. Earlier in his career, Sidhu founded a biotech that was sold to Roivant Sciences.
The SPAC plans to target healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences.
Sidhu's previous SPAC, JATT II Acquisition (JATT), completed a $60 million IPO in April 2026; two months later, it announced a merger agreement with preclinical biotech Talawar Therapeutics. Sidhu's earlier SPAC, JATT Acquisition, completed its combination with hair loss biotech Zura Bio (ZURA) in 2023.
The Westfield, NJ-based company was founded in 2026. It plans to list on the Nasdaq under the symbol JTTT. JATT III Acquisition filed confidentially on July 17, 2026. Guggenheim Securities is the sole bookrunner on the deal.
